Mutant bHLH Factors for Consistent Glial-to-Neuron Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for neuronal reprogramming to treat neurological conditions suffer from low efficiency and variable conversion rates, with bHLH genes' neurogenic potential being inhibited by environmental factors, leading to inconsistent outcomes in different brain regions and disease states.
Innovation Solution
Development of mutant basic-helix-loop-helix (bHLH) transcription factors with mutations in phosphoacceptor sites for proline-directed serine-threonine kinases and/or PKA phosphorylation sites, enhancing neuronal conversion efficiency by reducing inhibition, formulated in pharmaceutical compositions for direct intracranial administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type bHLH transcription factors are used for neuronal reprogramming, then the method is simple and easily administered, but the conversion efficiency is low and highly variable due to environmental inhibition
Solution Approach 1:
The patent applies parameter changes by mutating specific phosphoacceptor sites (serine or threonine residues) in the bHLH transcription factor protein sequence. These mutations alter the phosphorylation status parameters, preventing inhibitory phosphorylation by proline-directed serine-threonine kinases and PKA, thereby consistently enhancing neuronal conversion efficiency across different environmental conditions and brain regions.
2Adaptability or versatility
If bHLH genes are used to promote neurogenesis, then treatment potential is high, but environmental signals inhibit the ability of bHLH genes to function effectively
Solution Approach 1:
The patent converts the harmful inhibitory phosphorylation mechanism into a beneficial outcome by strategically mutating the phosphoacceptor sites. The mutations that eliminate phosphorylation sites prevent the harmful environmental inhibition while preserving the essential transcriptional activation function of bHLH genes, thereby enhancing their neurogenic potential in disease and injury models.
Solution Approach 2:
The patent changes the phosphorylation parameter of bHLH transcription factors by introducing mutations at conserved serine or threonine residues that serve as phosphoacceptor sites. This parameter change prevents inhibitory phosphorylation by environmental signals while maintaining the transcriptional activity necessary for neurogenesis, thereby converting environmental inhibition into enhanced functional performance.
3Ease of manufacture
If conventional bHLH gene therapy methods are used, then treatment approach is straightforward, but reprogramming efficiency is low and conversion rates are highly variable
Solution Approach 1:
The patent maintains the simplicity of gene therapy delivery while significantly improving reprogramming efficiency by changing the molecular parameter of the bHLH transcription factor through phosphoacceptor site mutations. The mutated transcription factors achieve consistent and enhanced conversion rates across different brain regions and disease states, resolving the contradiction between treatment simplicity and reprogramming efficiency.
Data Source
AI summary
The present application provides a mutant basic-helix-loop-helix (bHLH) transcription factor that comprises a mutation of one or more phosphoacceptor site for proline-directed serine-threonine kinases alone or together with a mutation in a conserved PKA site in the HLH domain, found in the corresponding wild-type bHLH transcription factor, and exhibits reduced phosphorylation by proline-directed serine-threonine kinases and PKA. Also provided are nucleic acids encoding the mutant bHLH transcription factor, and vectors comprising the encoding nucleic acids. Use of the mutant bHLH transcription factor or nucleic acid encoding the mutant bHLH transcription factor for therapeutic purposes can efficiently induce neuronal lineage conversion of glial cells, even in an inhibitory environment, and are useful in preventing or treating neurodegenerative diseases and disorders, and for treating CNS injuries. Further provided a use a ZBTB 18 transcription factor or a nucleic acid encoding the ZBTB 18 transcription factor for neuronal lineage conversion of glial cells.